Diapharm’s General Manager noted that, in particular, the United Kingdom is no longer suitable as a rapporteur for new marketing authorisations for medicinal products as part of the centralised procedure or as a Reference Member State for decentralised authorisation procedures (mutual recognition procedure; decentralised procedure). The United Kingdom did announce that it would initially adopt the EU legislation in force and only adapt it in line with its own ideas at a later date. However, it remains unclear, first of all, whether this announcement also applies to decisions taken by public authorities on such matters as medicinal products, Sibbing said. “And secondly, it is entirely uncertain how the United Kingdom plans to deal with new decisions relating to laws governing medicinal products after Brexit, such as judgements issued by the European Court of Justice,” Sibbing added as a word of warning to those in the audience.
CPhI China in Shanghai welcomes more than 30,000 visitors annually, making it one of the largest events for the pharmaceutical industry anywhere in the world. As a partner of the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Diapharm provides training courses at the exhibition every year for pharmaceutical companies from Asia that want to launch healthcare products on the European market.
(approx. 1,920 characters)